Altered expression of transforming growth factor-β1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix

Cancer

Volumn 77, Issue 6, 1996, Pages 1107-1114

  Comerci Jr , John T ^a   Runowicz, Carolyn D ^a   Flanders, Kathleen C ^b   De Victoria, Carol ^a   Fields, Abbie L ^a   Kadish, Anna S ^a   Goldberg, Gary L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cervical cancer; cervical dysplasia; neoplastic transformation; transforming growth factor 1

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSIS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 0029925083     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960315)77:6<1107::AID-CNCR16>3.0.CO;2-5     Document Type: Article

References (47)

1. Sporn MB, Roberts AB. Transforming growth factor-β: recent progress and new challenges. J Cell Biol 1992;119:1017-21.
2. Roberts AB, Thompson NL, Hein U, Flanders C, Sporn MB. Transforming growth factor-β: possible roles in carcinogenesis. Br J Cancer 1988;57:594-600.
3. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994;331:1286-91.
4. Flaumenhaft R, Abe M, Mignatti P, Rifkin DB. Basic fibroblast growth factor-induced activation of latent transforming growth factor β in endothelial cells: regulation of plasminogen activator activity. J Cell Biol 1992;118:901-9.
5. Miyazono K, Hellman U, Wernstedt C, Heldin CH. Latent high molecular weight complex of transforming growth factor-β1. Purification from human platelets and structural characterization. J Biol Chem 1988;263:6407-15.
6. Wakefield LM, Smith DM, Masui T, Harris CC, Sporn MB. Distribution and modulation of the cellular receptor for transforming growth factor-β. J Cell Biol 1987;105:965-75.
7. Moses HL, Young EY, Pietenpol JA. TGF-β stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990;63:245-7.
8. Coffey RJ, Bascome CC, Sipes NJ, Graves-Deal R, Weissman BE, Moses HL. Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor-β. Mol Cell Biol 1988;8:3088-93.
9. Shipely GD, Pittelkow MR, Wille JJ, Scott RE, Moses HL. Reversible inhibition of normal human prokeratinocyte proliferation by type β transforming growth factor inhibition in serum free medium. Cancer Res 1986; 46:2068-71.
10. Bascom CC, Wolfshohl RJ, Coffey RJ, Madisen NR, Webb NR, Purchio AR, et al. Complex regulation of transforming growth factor β1, β2, and β3 mRNA expression in mouse fibroblasts and keratinocytes by transforming growth factors β1 and β2. Mol Cell Biol 1989;9:5508-15.
11. Braun L, Durst M, Mikumo R, Gruppuso P. Differential response of nontumorigenic and tumorigenic human papillomavirus type 16-positive epithelial cells to transforming growth factor-β1. Cancer Res 1990;50:7324-32.
12. Braun L, Durst M, Mikumo R, Crowley A, Robinson M. Regulation of growth and gene expression in human papillomavirus-transformed keratinocytes by transforming growth factor β: implications for the control of papillomavirus infection. Mol Carcinogen 1992;6:100-11.
13. Yokota J, Tsukada Y, Nakajima T, Gotoh M, Shinosato Y, Mon N, Tsunokawa Y, et al. Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix. Cancer Res 1989;49:3598-601.
14. Scheffner M, Werness BA, Huibreytse JM, Levine AJ, Howley DM. The E6 oncoprotein encoded by human papiflomavirus types 16 and 18 promotes the degeneration of p53. Cell 1990;63:1129-36.
15. Crook T, Wrede D, Vousden KH. p53 Point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991;6:873-5.
16. Ferenczy A, Winkler B. Cervical intraepithelial neoplasia and condyloma. In: Blaustein's Pathology of the Female Genital Tract, 3rd Ed. Kurman RJ, editors. New York: Springer-Verlag, 1987; 177-217.
17. Flanders KC, Thompson NL, Cissel DS, van Obberghen-Schilling E, Baker CC, Kass ME, et al. Transforming growth factor-β1: histochemical localization with antibodies to different epitopes. J Cell Biol 1989; 108:653-60.
18. Kim SI, Lee HD, Bobbins PD, Busam K, Sporn MB, Roberts AB. Regulation of transforming growth factor β1 gene expression by the product of the retinoblastoma-susceptibility gene. Proc Natl Acad Sci USA 1991;88:3052-6.
19. Glick AB, Kulkarni AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, et al. Loss of expression of transforming growth factor β in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 1993;90:6076-80.
20. Fowlis DJ, Flanders KC, Duffie E, Balmain A, Akhurst RJ. Discordant transforming growth factor β1 RNA and protein localization during chemical carcinogenesis of the skin. Cell Growth Differ 1992;3:81-91.
21. Stamp GW, Nasim M, Cardillo M, Sudhindra SG, Lalani EN, Pignatelli M. Transforming growth factor beta distribution in basal cell carcinoma: relationship to proliferation index. Br J Dermatol 1993; 129:57-64.
22. Zenklusen JC, Stockman SL, Fischer SM, Conti CJ, Gimenez-Conti IB. Transforming growth factor-β1 expression in syrian hamster cheek pouch carcinogenesis. Mol Carcinogen 1994;9:10-6.
23. Kane CJ, Hebda PA, Mansbridge JN, Hanawalt PC. Direct evidence for spatial and temporal regulation of transforming growth factor beta 1 expression during cutaneous wound healing. J Cell Physiol 1991;148:157-73.
24. Kurstenberger GM, Rogers M, Schnapke R, Bauer G, Hofler P, Marks F. Stimulating role of transforming growth factors in multistage skin carcinogenesis: Possible explanation for the tumor-inducing effect of wounding in initiated NMRI mouse skin. Int J Cancer 1989;43:915-21.
25. Glick AB, Lee MM, Darwiche N, Kulkami AB, Karlsson S, Yuspa SH. Targeted deletion of the TGF-β1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 1994;8:2429-40.
26. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
27. Roberts AB, Sporn MB, Assian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986;83:4167-71.
28. Myrdol SE, Twarzdzik DR, Averspery N. Cell mediated coaction of transforming growth factors: incubation of type β with normal rat kidney cells produces a soluble activity that prolongs the ruffling response to type α. J Cell Biol 1986;102:1230-4.
29. Ignotz RA, Massagué J. Transforming growth factor-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 1986;261:4337-45.
30. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon, Derynck R, et al. Production of transforming growth factor β by human T-lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 1986;163:1037-50.
31. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, et al. Effects of transforming growth factor β on the functions of natural killer cells. Depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136:3916-20.
32. Sieweke MH, Thompson HL, Sporn MB, Bissell MJ. Mediation of wound-related Rous sarcoma virus tumorigenesis by TGF-β. Science 1990;248:1656-60.
33. Welch DR, Fabra A, Nakajima M. Transforming growth factor β stimulates mammary adenocarcinoma cell invasive and metastatic potential. Proc Natl Acad Sci USA 1990;87: 7678-82.
34. Akhurst RJ, Fee F, Balmain A. Localized production of TGF-β mRNA in tumor promoter-stimulated mouse epidermis. Nature 1988;331:363-5.
35. Kane CJ, Knapp AM, Mansbridge JN, Hanawalt PC. Transforming growth factor-beta 1 localization in normal and psoriatic epidermal keratinocytes in situ. J Cell Physiol 1990;144:144-50.
36. Escherick JS, DiCunto F, Flanders KC, Missero C, Dotto GP. Transforming growth factor β1 induction is associated with transforming growth factor β and β down modulation in 12-O-tetradecanoylphorbol-13-acetate-induced skin hyperplasia. Cancer Res 1993;53:5517-22.
37. Gomm JJ, Smith J, Ryall GK, Baillie R, Tumbull L, Coombes RC. Localization of basic fibroblast growth factor and transforming growth factor beta 1 in the human mammary gland. Cancer Res 1991;51:4185-92.
38. Nasiell K, Nasiell M, Vaclavinkova V. Behavior of moderate cervical dysplasia during long term follow-up. Obstet Gynecol 1983;61:609-14.
39. Nasiell K, Roger V, Nasiell M. Behavior of mild cervical dysplasia during long term follow-up. Obstet Gynecol 1986;67: 665-9.
40. Butta A, MacLennan K, Flanders KC, Sacks NPM, Smith I, McKinna A, et al. Induction of transforming growth factor β1 in human breast cancer in vivo following tamoxifen treatment. Cancer Res 1992;52:4261-4.
41. Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB. The growth inhibition of human breast cancer cells by a novel synthetic progestin involves the induction of transforming growth factor beta. J Clin Invest 1991;87:277-83.
42. Glick AB, McCune BK, Abdulkarem N, Flanders KC, Lumadue JA, Smith JM, et al. Complex regulation of TGF-β expression by retinoic acid in the vitamin A deficient rat. Development 1989;111:1081-6.
43. Ratko TA, Detrisac CJ, Dinger NM, et al. Chemopreventative efficacy of combined retinoid and tamoxifen treatment following surgical excision of a primary mammary cancer in female rats. Cancer Res 1989;49:4472-6.
44. Romney SL, Palan PR, Dattagupta C, Waggertheil, Smoller S, Wylie J, et al. Retinoids and the prevention of cervical dysplasias. Am J Obster Gynecol 1981; 141:890.
45. Graham V, Surwit ES, Weiner S, Meyskens FL. Phase II trial of beta-all-trans-retinoic acid for cervical intraepithelial neoplasia delivered via a collagen sponge and cervical cap. West J Med 1986; 145:192-5.
46. Meyskens FL, Surwit ES. Clinical experience with topical tretinoin in the treatment of cervical dysplasia. J Am Acad Dermatol 1986; 15:826-9.
47. Peng YM, Albert DA, Graham V, Surwit EA, Weiner S, Meyskens FL. Cervical tissue uptake of all-trans-retinoic acid delivered via a collagen sponge-cervical cap delivery device in patients with cervical dyspiasia. Invest New Drugs 1986;4:245-9.